ApoRepair is a French biotech company emerging from the National Center for Scientific Research (CNRS) that aims to improve the management of patients in the acute phase of myocardial infarction (MI). Reperfusion of the heart, essential to save the patient's life, generates adverse effects that diminish the expected benefit. Our therapeutic peptide protects the myocardium and improves the effects of reperfusion. This patented technology is based on a collaborative team effort spanning more than 15 years.
Company Details
- Employees
- 5
- Founded
- 2023
- Address
- 10 Place Françoise Héritier, Montpellier,34000,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://aporepair.fr/
- Keywords
- Montpellier.
- HQ
- Montpellier
Aporepair Questions
Aporepair's website is https://aporepair.fr/
Aporepair's LinkedIn profile is https://fr.linkedin.com/company/aporepair
Aporepair has
5 employees.
View email and phone details for 5
employees at Aporepair.
Aporepair's industry is
Biotechnology Research
Aporepair's top competitors are
Regenlife,
Novagray,
Nervosave Therapeutics,
Stent Up,
Nbx Bio,
Occical Therapeutics,
Greenphage,
Neurinnov,
Lineup Ocean,
Ai-Stroke.
Aporepair's categories are Biotechnology Research
Aporepair's founding year is 2023
